Corline Biomedical: Going global - Redeye

Redeye is positive about Corline’s and Kardium’s development with a new ten-year agreement, and that Kardium has now initiated the commercialisation of the Globe system. Furthermore, we have looked into Kardium’s opportunities outside of the US, revising our estimates, which have had a significantly positive impact on Corline’s valuation.

Länk till analysen i sin helhet: https://www.redeye.se/research/1129329/corline-biomedical-going-global?utm_source=finwire&utm_medium=RSS